• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种通过注射胶原酶治疗由杜普伊特伦病引起的严重挛缩近端指间关节并提高矫正效果的治疗方案的效果。

The effect of a therapy protocol for increasing correction of severely contracted proximal interphalangeal joints caused by dupuytren disease and treated with collagenase injection.

作者信息

Skirven Terri M, Bachoura Abdo, Jacoby Sidney M, Culp Randall W, Osterman A Lee

机构信息

Philadelphia Hand Center, Thomas Jefferson Medical College, Philadelphia, PA 21218, USA.

出版信息

J Hand Surg Am. 2013 Apr;38(4):684-9. doi: 10.1016/j.jhsa.2013.01.038. Epub 2013 Mar 6.

DOI:10.1016/j.jhsa.2013.01.038
PMID:23474162
Abstract

PURPOSE

To determine the effect of a specific orthotic intervention and therapy protocol on proximal interphalangeal (PIP) joint contractures of greater than 40° caused by Dupuytren disease and treated with collagenase injections.

METHODS

All patients with PIP joints contracted at least 40° by Dupuytren disease were prospectively invited to participate in the study. Following standard collagenase injection and cord rupture by a hand surgeon, a certified hand therapist evaluated and treated each patient based on a defined treatment protocol that consisted of orthotic intervention to address residual PIP joint contracture. In addition, exercises were initiated emphasizing reverse blocking for PIP joint extension and distal interphalangeal joint flexion exercises with the PIP joint held in extension to lengthen a frequently shortened oblique retinacular ligament. Patients were assessed before injection, immediately after injection, and 1 and 4 weeks later. There were 22 fingers in 21 patients. The mean age at treatment was 63 years (range, 37-80 y).

RESULTS

The mean baseline passive PIP joint contracture was 56° (range, 40° to 80°). At cord rupture, the mean PIP joint contracture became 22° (range, 0° to 55°). One week after cord rupture and therapy, the contracture decreased further to a mean of 12° (range, 0° to 36°). By 4 weeks, the mean contracture was 7° (range, 0° to 35°). The differences in PIP joint contracture were statistically significant at all time points except when comparing the means at 1 week and 4 weeks. The results represent an 88% improvement of the PIP joint contracture.

CONCLUSIONS

In the short term, it appears that severe PIP joint contractures benefit from specific, postinjection orthotic intervention and targeted exercises.

TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic IV.

摘要

目的

确定一种特定的矫形干预和治疗方案对由杜普伊特伦病引起且经胶原酶注射治疗的大于40°的近端指间(PIP)关节挛缩的影响。

方法

前瞻性邀请所有因杜普伊特伦病导致PIP关节挛缩至少40°的患者参与本研究。在手部外科医生进行标准的胶原酶注射和条索切断术后,一名经过认证的手部治疗师根据既定的治疗方案对每位患者进行评估和治疗,该方案包括针对残留PIP关节挛缩的矫形干预。此外,开始进行锻炼,重点是PIP关节伸展的反向阻滞以及在PIP关节伸展时进行远端指间关节屈曲锻炼,以拉长经常缩短的斜支持韧带。在注射前、注射后即刻、注射后1周和4周对患者进行评估。21例患者共22指。治疗时的平均年龄为63岁(范围37 - 80岁)。

结果

基线时PIP关节被动挛缩的平均值为56°(范围40°至80°)。在条索切断时,PIP关节挛缩的平均值变为22°(范围0°至55°)。条索切断和治疗1周后,挛缩进一步降至平均值12°(范围0°至36°)。到4周时,平均挛缩为7°(范围0°至35°)。除比较1周和4周时的平均值外,PIP关节挛缩在所有时间点的差异均具有统计学意义。结果显示PIP关节挛缩改善了88%。

结论

短期内,严重的PIP关节挛缩似乎受益于特定的注射后矫形干预和针对性锻炼。

研究类型/证据水平:治疗性IV级。

相似文献

1
The effect of a therapy protocol for increasing correction of severely contracted proximal interphalangeal joints caused by dupuytren disease and treated with collagenase injection.一种通过注射胶原酶治疗由杜普伊特伦病引起的严重挛缩近端指间关节并提高矫正效果的治疗方案的效果。
J Hand Surg Am. 2013 Apr;38(4):684-9. doi: 10.1016/j.jhsa.2013.01.038. Epub 2013 Mar 6.
2
Efficacy and safety of collagenase clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies.溶组织梭状芽孢杆菌胶原酶注射治疗掌腱膜挛缩症的疗效与安全性:两项开放标签研究的短期结果
J Hand Surg Am. 2013 Jan;38(1):2-11. doi: 10.1016/j.jhsa.2012.10.008. Epub 2012 Dec 4.
3
Efficacy and safety of collagenase clostridium histolyticum in the treatment of proximal interphalangeal joints in dupuytren contracture: combined analysis of 4 phase 3 clinical trials.溶组织梭状芽孢杆菌胶原酶治疗掌腱膜挛缩症近端指间关节的疗效及安全性:4项3期临床试验的综合分析
J Hand Surg Am. 2015 May;40(5):975-83. doi: 10.1016/j.jhsa.2015.02.018. Epub 2015 Apr 2.
4
Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren's contracture.注射用混合胶原酶亚型治疗掌腱膜挛缩症的疗效与安全性。
J Hand Surg Am. 2007 Jul-Aug;32(6):767-74. doi: 10.1016/j.jhsa.2007.04.002.
5
Short-term efficacy and safety of collagenase injection for Dupuytren's contracture: Therapy protocol for successful outcomes in a clinical setting.胶原酶注射治疗掌腱膜挛缩症的短期疗效与安全性:临床环境中成功治疗的方案
J Orthop Sci. 2019 May;24(3):434-440. doi: 10.1016/j.jos.2018.10.015. Epub 2018 Nov 2.
6
Collagenase injection as nonsurgical treatment of Dupuytren's disease: 8-year follow-up.胶原酶注射作为杜普伊特伦挛缩症的非手术治疗:8年随访
J Hand Surg Am. 2010 Apr;35(4):534-9, 539.e1. doi: 10.1016/j.jhsa.2010.01.003.
7
Efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple Dupuytren contractures.溶组织梭状芽孢杆菌胶原酶联合注射治疗多发杜普伊特伦挛缩症的疗效与安全性
J Hand Surg Am. 2014 Jan;39(1):57-64. doi: 10.1016/j.jhsa.2013.10.002. Epub 2013 Dec 4.
8
Prospective randomized controlled trial comparing 1- versus 7-day manipulation following collagenase injection for dupuytren contracture.比较胶原酶注射治疗掌腱膜挛缩症后1天与7天手法治疗的前瞻性随机对照试验。
J Hand Surg Am. 2014 Oct;39(10):1933-1941.e1. doi: 10.1016/j.jhsa.2014.07.010. Epub 2014 Sep 4.
9
Collagenase injections for Dupuytren's disease: prospective cohort study assessing 2-year treatment effect durability.胶原酶注射治疗掌腱膜挛缩症:评估两年治疗效果持久性的前瞻性队列研究
BMJ Open. 2017 Mar 15;7(3):e012943. doi: 10.1136/bmjopen-2016-012943.
10
Collagenase injections for Dupuytren disease: 3-year treatment outcomes and predictors of recurrence in 89 hands.胶原酶注射治疗杜普伊特伦挛缩症:89 只手的 3 年治疗结果和复发预测因素。
Acta Orthop. 2019 Dec;90(6):517-522. doi: 10.1080/17453674.2019.1663472. Epub 2019 Sep 10.

引用本文的文献

1
Clinical Outcomes of Collagenase Injections in Management of Dupuytren Contracture of the Proximal Interphalangeal Joint.胶原酶注射治疗近端指间关节掌腱膜挛缩症的临床疗效
J Hand Surg Glob Online. 2024 Jul 9;6(5):627-630. doi: 10.1016/j.jhsg.2024.05.009. eCollection 2024 Sep.
2
Nonoperative Treatment of Dupuytren's Contracture: The Use of Ultrasound Imaging to Assess Efficacy.掌腱膜挛缩症的非手术治疗:使用超声成像评估疗效。
J Hand Microsurg. 2024 Apr 16;16(1):100003. doi: 10.1055/s-0042-1748780. eCollection 2024 Mar.
3
A Personalized Approach to Treat Advanced Stage Severely Contracted Joints in Dupuytren's Disease with a Unique Skeletal Distraction Device-Utilizing Modern Imaging Tools to Enhance Safety for the Patient.
一种采用独特骨骼牵张装置治疗杜普伊特伦挛缩症晚期严重挛缩关节的个性化方法——利用现代成像工具提高患者安全性。
J Pers Med. 2022 Mar 1;12(3):378. doi: 10.3390/jpm12030378.
4
Hand therapy or not following collagenase treatment for Dupuytren's contracture? Protocol for a randomised controlled trial.手部治疗或不治疗杜普伊特伦挛缩症的胶原酶治疗?一项随机对照试验的方案。
BMC Musculoskelet Disord. 2019 Aug 28;20(1):387. doi: 10.1186/s12891-019-2712-z.
5
Collagenase Treatment in Dupuytren Contractures: A Review of the Current State Versus Future Needs.胶原酶治疗掌腱膜挛缩症:现状与未来需求综述
Rheumatol Ther. 2016 Jun;3(1):43-51. doi: 10.1007/s40744-016-0027-1. Epub 2016 Feb 3.
6
Collagenase clostridium histolyticum in Dupuytren's contracture: a systematic review.溶组织梭状芽孢杆菌胶原酶治疗掌腱膜挛缩症:一项系统评价
Br Med Bull. 2016 Jun;118(1):149-58. doi: 10.1093/bmb/ldw020. Epub 2016 May 5.
7
What are we measuring? A critique of range of motion methods currently in use for Dupuytren's disease and recommendations for practice.我们在测量什么?对目前用于杜普伊特伦挛缩症的活动度测量方法的批判及实践建议。
BMC Musculoskelet Disord. 2016 Jan 13;17:20. doi: 10.1186/s12891-016-0884-3.
8
Clinical outcomes following collagenase injections compared to fasciectomy in the treatment of Dupuytren's contracture.与筋膜切除术相比,胶原酶注射治疗掌腱膜挛缩症后的临床疗效。
Hand (N Y). 2015 Jun;10(2):260-5. doi: 10.1007/s11552-014-9704-0.
9
Collagenase treatment of Dupuytren's contracture using a modified injection method: a prospective cohort study of skin tears in 164 hands, including short-term outcome.采用改良注射方法的胶原酶治疗掌腱膜挛缩症:164只手皮肤撕裂的前瞻性队列研究,包括短期结果
Acta Orthop. 2015 Jun;86(3):310-5. doi: 10.3109/17453674.2015.1019782. Epub 2015 Feb 19.
10
Postapproval clinical experience in the treatment of Dupuytren's contracture with collagenase clostridium histolyticum (CCH): the first 1,000 days.溶组织梭菌胶原酶(CCH)治疗杜普伊特伦挛缩症的批准后临床经验:最初1000天
Hand (N Y). 2014 Dec;9(4):447-58. doi: 10.1007/s11552-014-9645-7.